Navigation Links
Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Date:1/13/2014

INDIANAPOLIS, Jan. 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two processes that have been implicated in migraine headaches. Lilly's CGRP antibody is a biologic entity injected subcutaneously that binds and inhibits the activity of CGRP, which is released during activation of sensory neurons involved in pain signaling.

This novel molecule (LY2951742) was discovered by Lilly scientists and then licensed to Arteaus Therapeutics for development in the clinical proof-of-concept study. Financial terms of the deal were not disclosed.

Arteaus was formed in 2011 with an $18 million investment from Atlas Venture and OrbiMed, upon acquiring the rights to develop Lilly's CGRP antibody. Licensing Lilly's CGRP antibody to Arteaus was part of Lilly's alternative risk-sharing strategy, which includes participation in the Capital Funds Portfolio. The Capital Funds Portfolio comprises virtual project-focused companies, financed by independent investment funds that acquire early-stage molecules to develop through proof-of-concept (one or more clinical studies designed to determine whether a molecule has the potential to work in patients). If the molecule shows efficacy, the molecule and/or development rights are offered for sale to biopharmaceutical companies.

"Of the nine project-focused companies currently in the Capital Funds Portfolio, Arteaus is the first to reach proof-of-concept and to achieve positive results. Through this strategy, independent investment firms and portfolio companies provide a unique way
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers ... technologies must be able to protect their ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... of the Medical Device Industry, it steadfastly ... sectors of cases involving IP infringement. This ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ... cells. VSRNAs are of molecular size less than 10 ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ... growth of these markets. The European ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Therapeutics (NYSE Amex: CXM ) today provided an ... Pharmaceuticals, business assets in connection with a proposed asset purchase ... on June 27, 2011, the completion of such an asset ... of the bankruptcy court.  In an effort to expedite the ...
... Corporation,s (NYSE: BSX ) Board of Directors ... up to $1.0 billion of its common stock and ... existing share repurchase program. "This repurchase program ... long-term business prospects, earnings growth potential and our ability ...
Cached Medicine Technology:Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... the answer to one open-ended question predicted the teenagers, offending ... think you,ll live?", According to the study, having little hope ... Piquero said the study found those who don,t view a ... rates and commit more serious offenses, while those who believe ... less., "In a lot of distressed communities and for a ...
(Date:4/14/2014)... a molecule that is a probable driving force in ... an important target for colorectal cancer treatment and a ... microRNA-135b (miR-135b) in two animal models and human tumors ... and was led by researchers at The Ohio State ... Hospital and Richard J. Solove Research Institute (OSUCCC ...
(Date:4/14/2014)... Depression can hit young fathers hard -- with symptoms increasing ... children,s lives, a new Northwestern Medicine study has found. , ... first five years of fatherhood for these young men, who ... whom lived in the same home as their children. The ... journal Pediatrics . , This study is the first ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... to Accelerate Sales of the New, Fully Nano-Encapsulated Liquid Vitamin, ... and COLUMBUS, Ohio, June 23 livethesource(TM) announced ... has joined the company,s distribution network to help ... its breakthrough technology, daily source(TM) is a complete ...
... suggests a direct link between smoking and brain damage will ... of Neurochemistry . Researchers, led by Debapriya Ghosh and Dr ... have found that a compound in tobacco provokes white blood ... leading to severe neurological damage. The research centers ...
... Each year hospital operating rooms face increasingly difficult ... more demanding. Saint Vincent Health Center (SVHC) in ... provided by Eclipsys Corp. and powered by Surgical Information ... and national averages for quality measures. , , ...
... Derma Sciences, Inc. (OTC ... products, announced today that it has begun shipping BIOGUARD(TM) ... that it has been awarded reimbursement codes for the ... BIOGUARD will offer surgeons, wound care clinicians, infection ...
... WASHINGTON, June 23 A study released earlier this month ... Ohio University found that medical bills are involved ... 50 percent just six years ago. Additionally, more than 75 ... overwhelmed by the out-of-pocket expenses. In the wake of these ...
... Center offers more services to autistic community with the help ... Judson Center ( www.judsoncenter.org ), a comprehensive ... of individuals and families, today opens the newly-constructed Autism Center ... headquarters. Judson Center employees, autism advocates and families as ...
Cached Medicine News:Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 2Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 3Health News:New research discovers link between smoking and brain damage 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 2Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 4Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 2Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 3Health News:Judson Center Celebrates Grand Opening of its New Autism Center 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: